Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 5/20 | 0.57 |
| ▸ | HTT | P42858 | 3/20 | 0.55 |
| ▸ | NR2C2 | P49116 | 8/20 | 0.54 |
| ▸ | HCK | P08631 | 7/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | GCK | P35557 | 2/20 | 0.54 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.54 |
| ▸ | FES | P07332 | 1/20 | 0.54 |
| ▸ | FER | P16591 | 1/20 | 0.54 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | CLK1 | P49759 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22337466 | 0.96 | ABL1 (0.58) | BRAFHCKABL1EGFR | |
| SCHEMBL1841461 | 0.89 | BRAF (0.69) | BRAFHCK | |
| SCHEMBL1825894 | 0.88 | BRAF (0.58) | BRAFHCKMAPK14 | |
| SCHEMBL1826267 | 0.88 | BRAF (0.65) | BRAFNR2C2HCKGCKMAP3K7 | |
| SCHEMBL13291949 | 0.87 | NR2C2 (0.64) | BRAFHTTNR2C2HCKMAPK1 | |
| SCHEMBL3229925 | 0.87 | BRAF (0.66) | BRAFHCKMAPK14 | |
| SCHEMBL3234828 | 0.87 | NR2C2 (0.59) | BRAFHTTNR2C2HCKMAPK1 | |
| SCHEMBL22337178 | 0.86 | BRAF (0.56) | BRAFHCKMAPK14 | |
| SCHEMBL19152879 | 0.86 | BRAF (0.55) | BRAFHCKMAPK14 | |
| SCHEMBL1833165 | 0.85 | LCK (0.66) | BRAFHCKMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758892-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2012-10-17 | — | — | EP | claimed |
| US-7745437-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2010-06-29 | — | — | US | claimed |
| US-20070225286-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2007-09-27 | — | — | US | claimed |
| US-20220305016-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS FOR TREATING OSTEOPOROSIS | THE GENERAL HOSPITAL CORPORATION (US) | 2022-09-29 | — | — | US | disclosed |
| US-20220133736-A1 | USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2022-05-05 | — | — | US | disclosed |
| US-11241435-B2 | Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis | THE GENERAL HOSPITAL CORPORATION (US) | 2022-02-08 | — | — | US | disclosed |
| US-20210147388-A1 | IMIDAZOLYL KINASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-05-20 | — | — | US | disclosed |
| US-10975058-B2 | Imidazolyl kinase inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| EP-3171874-B1 | IMIDAZOLYL KINASE INHIBITORS AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2020-11-18 | — | — | EP | disclosed |
| US-20200338087-A9 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-20200253981-A1 | USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2020-08-13 | — | — | US | disclosed |
| WO-2016023014-A2 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-11 | — | — | WO | disclosed |
| WO-2016014542-A1 | IMIDAZOLYL KINASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-01-28 | — | — | WO | disclosed |
| EP-1758892-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2012-10-17 | — | — | EP | disclosed |
| US-7745437-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2010-06-29 | — | — | US | disclosed |
| US-7745437-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2010-06-29 | — | — | US | disclosed |
| US-7745437-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2010-06-29 | — | — | US | disclosed |
| US-20070225286-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2007-09-27 | — | — | US | disclosed |
| EP-1758892-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005123719-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133736-A1 | USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS | SIK2, SIK1, SIK3 | BRAF 206/4885HTT 4191/4885NR2C2 3350/4885 |
| US-20200253981-A1 | USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS | SIK2, SIK1, SIK3 | BRAF 206/4885HTT 4191/4885NR2C2 3350/4885 |
| US-20220305016-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS FOR TREATING OSTEOPOROSIS | SOST, SIK2, SIK1 | BRAF 1160/4885HTT 3638/4885NR2C2 1033/4885 |
| US-10975058-B2 | Imidazolyl kinase inhibitors and uses thereof | PRKACB, PRKACG, PRKACA | BRAF 151/4885HTT 1462/4885NR2C2 2518/4885 |
| US-11241435-B2 | Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis | SOST, SIK2, SIK1 | BRAF 1160/4885HTT 3638/4885NR2C2 1033/4885 |
| US-20210147388-A1 | IMIDAZOLYL KINASE INHIBITORS AND USES THEREOF | PRKACB, PRKACG, PRKACA | BRAF 151/4885HTT 1462/4885NR2C2 2518/4885 |
| US-20200338087-A9 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | SIK1, SIK3, SIK2 | BRAF 481/4885HTT 4494/4885NR2C2 3084/4885 |
| US-20070225286-A1 | Compounds and Compositions as Protein Kinase Inhibitors | BMX, PTK2B, SRC | BRAF 17/4885HTT 2165/4885NR2C2 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.